当前位置:循环首页>正文

[CIT2015]促进先进影像技术联用--大会联合主席、比利时阿尔斯特心血管中心William Wijns教授专访

作者:  W.Wijns   日期:2015/3/23 15:16:25

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

编者按:本次CIT2015特邀讲者多达791位。在现场,《国际循环》采访到大会联合主席、比利时阿尔斯特心血管中心William Wijns教授,他表示,他相信CIT对创新的体现,必将为国外介入医疗带来很多启示。

  International Circulation: Imaging and Physiology is the focus in clinical practices, such as FFR, IVUS and OCT-based optimized PCI is still the controversy. How do you evaluate these image technologies, which details should be noticed in PCI optimization?

  《国际循环》:血管内影像和生理学特色一直是临床争议的焦点。如FFR、IVUS和OCT指导在PCI优化中的作用孰轻孰重的争论一直在继续。您如何评价几种影像学方法对不同冠状动脉病变PCI的指导作用,能优化哪些细节?

  Dr. Wijns : Thank you. Thank you very much for the opportunity to meet and to interact with colleagues in China. The concept of optimizing PCI is becoming more and more of interest to physicians because we start to see the first results indicating that when you use physiology, for instance FFR, and also imaging, for instance IVUS, but I even prefer OCT, when using these physiologic and imaging techniques, complex cases can benefit from even better results. This is for two reasons, we can identify better which lesions to treat, how long the stent should be, so there is help for procedure planning, and there is also on site at the end of the case, the opportunity to document that we have done a good job and that we do not leave the patient with inappropriate deployment, age dissections and prolapsing thrombus. All these situations may lead to early events like periprocedural infarction or late problems like stent thrombosis.

  DrWijns: I can say more if you want. I can just start again now. I said we are starting to see the evidence coming up because we have very powerful imaging techniques that can easily be understood by the physician during the procedure and we also see data accumulating indicating the link between what we see on the image and adverse or good outcome. We can anticipate that the time is about right to design a prospective trial where angiographic guidance only will be compared with angiographic guidance supported by physiology and imaging to eventually find out which patients benefit from these additional tools.

  Wijns教授:非常感谢你们提供这样一个机会使我有幸能够与中国同道见面和交流。我们发现,应用生理技术[如血流储备分数(FFR)]及影像学技术[如血管内超声(IVUS)以及我个人更喜欢的光学相干断层成像(OCT)]可使复杂冠脉病变患者获益,获得更好的临床结局。因此,优化PCI的理念受到越来越多临床医生的关注与重视。通过应用上述技术进行优化PCI我们能够更好地确定哪些病变需要治疗,需要置入多长的支架,这对我们制定手术计划是非常有帮助的。另外,在PCI手术后应用上述技术有助于我们确定自己成功实施了PCI,患者得到了适当的处置以及未发生夹层及血栓脱垂等,从而避免围术期梗死等早期并发症及晚期并发症如支架血栓形成如果需要的话,我可以多谈一些。我们现在已经拥有了非常强大的且在PCI手术期间能够易于临床医生理解的影像学技术,越来越多的数据提示“影像学结果与不良或良好结局之间存在相关性”。可以预见,是时候设计有关单用血管造影指导PCI与血管造影与生理及影像学技术联用指导PCI的前瞻性对比试验并最终确定哪些患者能从联用生理及影像学技术中获益了。

  International Circulation: Chinese late breaking trials are one of the most important projects in CIT, what’s your view in these new trials presented in the conference?

  《国际循环》:中国最新试验已成为CIT的重点项目之一,您如何评价在会上公布的几项最新中国原创试验?

  Dr. Wijns: Yes, it is my third visit to CIT, I am very much looking forward to it. I actually like the concept that the acronym CIT stands for;Cfor cooperation, I for innovation, and T for transformation. Cooperation is really important because we learn a lot from each other because interventional medicine is a very practical discipline we really learn from each other’s experience and of course colleagues here in China have large, massive, experience in terms of patient load so we learn from them. Also I am really impressed by the innovation that is being presented here at CIT, atleast when I cam previously and I trust it will be the same this year. I am looking forward to the meeting. It is a great opportunity to interact, meeting, learn to know colleagues here, and actually further to one of my previous visits, I met a colleague and presently we are collaborating and cooperating in a randomized trial about the innovation technology that we hope will be transformative, like CIT.

  Wijns教授:我已经是第三次参加CIT,对CIT大会非常期待。实际上,我非常喜欢CIT这个缩写所代表的真正含义,即C代表着合作,I代表着创新,T代表着转化。合作无疑是非常重要的,有助于大家相互学习。介入医学是一门非常实用的学科,大家相互之间需要相互交流,学习彼此的经验。中国有着庞大的患者群体,中国同道积累了非常丰富的经验,因此我们需要向他们学习。另外,从往届大会的经历来看,CIT大会所体现的创新也令我印象深刻,我想今年的CIT大会应该同样能够非常好地体现创新性。我对本届CIT是非常期待的,它无疑能为大家提供了一个相互交流、见面与学习的机会。我现在就正在跟之前通过参加CIT大会所认识的一位同道合作开展一项随机有关创新技术的随机试验。希望能够像CIT大会所注重的那样,我们合作开展的这项研究能够被转化应用于临床。

 

版面编辑:宁梦曼  责任编辑:徐竞鸥


IVUSFFROCT创新随机试验

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530